Skip to main content
OCPNF logo

Olympus Corporation (OCPNF) Stock Price & Analysis

Olympus Corporation (OCPNF) — price $11.53 (0.00%), as of the Nov 19, 2026 trading session; market cap $12.3B. Expected results Feb 12, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$11.53 $0.00 (0.00%) Market Cap $12.3B

Olympus Corporation · OCPNF · Healthcare · Medical - Devices

Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SNN · Smith & Nephew plc · 84 /100
  • PEN · Penumbra, Inc. · 92 /100
  • ALGN · Align Technology, Inc. · 83 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$11.53
Change on the day0.00%
52-week range$8.00–$14.00
Market capitalisation$12.3B—
Price / earnings (trailing)21.38
Shares traded on the day2.0K
Beta (volatility vs the S&P 500)0.2
Dividends per share (last 12 months)$0.38
Dividend yield (last 12 months)3.29%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $8.00, high $14, latest $12. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $14 $8.00 high $14 Feb 13, 2026 · Earnings results · reported below the recorded estimate · close $121May 12, 2026 · Earnings results · reported above the recorded estimate · close $102Aug 7, 2026 · Earnings results · reported above the recorded estimate · close $123Nov 10, 2026 · Earnings results · reported above the recorded estimate · close $124 Oct 17, 2025 Nov 19, 2026 · $12 $12Oct 17, 2025$12Oct 31, 2025$14Nov 14, 2025$13Nov 28, 2025$12Dec 12, 2025$13Dec 26, 2025$13Jan 9, 2026$11Jan 23, 2026$12Feb 6, 2026$10Feb 20, 2026$8.00Mar 6, 2026$8.61Mar 20, 2026$9.33Apr 2, 2026$9.49Apr 17, 2026$9.49May 1, 2026$10May 15, 2026$11May 29, 2026$11Jun 12, 2026$10Jun 26, 2026$11Jul 10, 2026$11Jul 24, 2026$12Aug 7, 2026$13Aug 21, 2026$13Sep 4, 2026$12Sep 18, 2026$12Oct 2, 2026$11Oct 16, 2026$11Oct 30, 2026$12Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleFeb 12, 2027, Next results due; Mar 30, 2027, Ex-dividend date; Mar 30, 2027, Dividend payment date. Spacing is order only and carries no duration.Nov 19, 20261Feb 12, 20272Mar 30, 20273Mar 30, 2027
  1. Next results dueProvider estimate
  2. Ex-dividend dateCompany record
  3. Dividend payment dateCompany record
How to read these dates

Events are in date order; the spacing is not a duration scale. Estimated dates can change.

What to watch next

Other perspectives

Council score for Olympus (OCPNF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Olympus (OCPNF), and what does it report?

Short answer

Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments. Healthcare / Medical Devices Headquarters: 2951, Ishikawa-machi, Hachioji, TY, 192-8507, JP. It employs 28,138 people and is led by Robert White. In Q1 FY2027 it reported revenue of ¥238.66B and net income of ¥18.96B. The market values it at $12.3B.

2 · Latest results

What do the latest results show for Olympus (OCPNF)?

Short answer · as of

The most recent reported quarter, Q1 FY2027, carried revenue of ¥238.66B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.71B Nov 10, 2026
Latest report · revenue estimate
$1.70B Nov 10, 2026
Latest report · revenue vs estimate
Above estimate Nov 10, 2026
Latest report · EPS vs estimate
Above estimate Nov 10, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 10, 2026$1.71B$1.70B$0.1971$0.1407
Aug 7, 2026$1.48B$1.39B$0.1092$0.0531
May 12, 2026$1.86B$1.78B$0.1414$0.0482
Feb 13, 2026$1.67B$1.66B$0.0821$0.1471
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2027¥238.66B¥18.96B¥17.76 (diluted)
Q4 FY2026¥297.14B¥24.97B¥22.37 (diluted)
Q3 FY2026¥261.27B¥14.18B¥12.85 (diluted)
Q2 FY2026¥247.84B¥20.20B¥18.05 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Olympus (OCPNF)?

Short answer · as of

The distress and quality screens read Altman Z 3.31 · Piotroski F 7. Trailing ratios: ROE 11.8% · ROA 6.0% · current ratio 1.67 · earnings yield 4.8% · free-cash-flow yield 4.6%.

4 · What to check next?

What should you watch next at Olympus (OCPNF)?

Short answer · as of

The next earnings report is expected on Feb 12, 2027.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is Olympus scored?

Research dated 2026-09-13.

Olympus differs from a disposable-focused device supplier because its model joins complex endoscopy platforms with procedure tools, reprocessors, repair, maintenance, and system integration. A system placement can support later clinical use and service activity, so the commercial relationship can persist beyond the original equipment shipment.

It also differs from a narrowly clinical manufacturer through microscopes and industrial inspection technologies. Investors comparing Olympus with medical-device peers are therefore comparing a mixed installed-base and precision-instrument model, not merely a stream of surgical product sales.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Sartorius AG (SSSGY) Named competitor$43.93 Nov 19, 2026$15.2B— Model unavailable
Shionogi & Co., Ltd. (SGIOY) Named competitor$9.81 Nov 18, 2026$16.7B— Model unavailable
Fisher & Paykel Healthcare Corporation Limited (FSPKF) Named competitor$26.99 Nov 19, 2026$15.9B— Model unavailable
Eurofins Scientific SE (ERFSF) Named competitor$93.89 Nov 19, 2026$16.1B— Model unavailable
CSPC Pharmaceutical Group Limited (CHJTF) Named competitor$1.12 Nov 19, 2026$12.8B— Model unavailable
Smith & Nephew plc (SNN) Same industry, near in market value$29.83 Nov 19, 2026$12.5B— 5-pillar · not comparable
Penumbra, Inc. (PEN) Same industry, near in market value$320.00 Nov 19, 2026$12.6B— 5-pillar · not comparable
Align Technology, Inc. (ALGN) Same industry, near in market value$163.96 Nov 18, 2026$11.6B— 5-pillar · not comparable
Glaukos Corporation (GKOS) Same industry, near in market value$233.08 Nov 18, 2026$13.8B— 5-pillar · not comparable
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$370.17 Nov 18, 2026$9.95B— 5-pillar · not comparable
Insulet Corporation (PODD) Same industry, near in market value$139.98 Nov 18, 2026$9.71B— 5-pillar · not comparable
Bruker Corporation (BRKR) Same industry, near in market value$62.10 Nov 19, 2026$9.48B— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held OCPNF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported OCPNF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Olympus (OCPNF)?

Read these with our analysis →

OCPNF Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

Why do Olympus endoscope repair services matter to the business model?

Repair and maintenance keep endoscopy systems in use and extend Olympus's relationship with the installed base beyond the equipment sale. That service connection can accompany demand for procedure tools, reprocessors, and system integration.

Does Olympus rely solely on hospital endoscopy systems?

Hospital endoscopy is only part of the product set. Olympus also sells therapeutic devices, microscopes, industrial videoscopes, testing equipment, analyzers, biomedical materials, orthopedic equipment, and related services.

What is the OCPNF stock price today?

The last price recorded for Olympus Corporation (OCPNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Does OCPNF pay a dividend?

Yes. The dividend yield of Olympus Corporation (OCPNF) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 41 figures on this page — 32 from Financial Modeling Prep (FMP), 4 with no recorded source, 4 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • 5. How is Olympus scored?: Business description; Sector / industry (provider taxonomy)
  • FAQ: Why do Olympus endoscope repair services matter to the business model?: Business description
  • FAQ: Does Olympus rely solely on hospital endoscopy systems?: Business description; Sector / industry (provider taxonomy)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.